Dexketoprofen Trometamol Plus Sufentanil for Analgesia After Thoracoscopic Radical Resection of Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial.
Ao Guo, Mengting Shen, Hanbin Wang et al.
✦ AI-curated · Sources linked
From the abstract
Evidence for adding dexketoprofen trometamol to sufentanil-based patient-controlled intravenous analgesia (PCIA) after thoracoscopic radical resection of lung cancer remains limited. To evaluate 48-hour opioid consumption, pain outcomes, and short-term adverse events with dexketoprofen trometamol plus sufentanil versus sufentanil-based PCIA alone.
Reported results
Sufentanil consumption was lower in Group R than in Group S (78.03 ± 10.66 vs 96.78 ± 13.69 μg; reduction 18.75 μg, 95% CI 13.61 to 23.89; P<0.001), representing an approximately 19% reduction. Resting pain scores were lower at 12 and 24 hours (both P=0.004), meeting the revised Bonferroni threshold of P<0.005 for 10 time-point comparisons; the coughing-pain difference at 12 hours (P=0.006) did not meet this…
Authors' conclusions
Adding dexketoprofen trometamol reduced 48-hour sufentanil consumption in the analyzed population. Pain differences were time-specific secondary findings and did not establish sustained analgesic superiority. The nausea finding requires confirmation, and the trial was insufficient to establish safety for uncommon adverse events.